ViTAA Medical Solutions is pleased to announce that as of April 1, 2023, Mr. Martin Sylvain has joined ViTAA’s Board of Directors. Mr. Sylvain has extensive experience and accomplishments in the aortic aneurysm field through over 30 years’ experience at Gore Medical where he led the Company’s commercialization efforts from 1983-2019. During that period, he led the growth of Gore’s business to become the Global leader in the vascular stent graft market. Since his recent retirement from Gore, he has become an advisor to the two largest vascular surgery meetings in the world, the VEITH Symposium (New York) and the Charing Cross Symposium (London, UK). Mr. Sylvain has also had the distinct honor to be made the only non-physician honorary member of the Society of Clinical Vascular Surgery and is an Affiliate Member of the SVS (Society of Vascular Surgery). In addition, Mr. Sylvain previously served as a Board member of the Society of Vascular Surgery Foundation.

“I am thrilled to join ViTAA’s Leadership Team at this very important stage of the Company’s development”, says Mr. Sylvain. “ViTAA’s AI-based technology addresses a significant unmet clinical need in vascular surgery by identifying AAA patients at risk and eventually predicting and mitigating complications associated with their surgical interventions”.

“The addition of Mr. Sylvain to ViTAA’s Board of Directors is the beginning of efforts to fortify the oversight and strategic direction of the Company as it enters the stage of early commercialization across North America”, says Steven Arless, recently appointed Executive Chairman of ViTAA’s Board. “Mr. Sylvain’s track record with Gore speaks for itself, and we are very fortunate to have him on ViTAA’s Board to help navigate and optimize the business opportunities which lie ahead.”

“Mr. Sylvain is a perfect addition to our governance”, says Mitchel Benovoy, CEO. “His experience and wisdom are second-to-none in the vascular space and I couldn’t be more excited to work with him on taking ViTAA to the next level.”.

About ViTAA Medical Solutions Inc.

Founded by medical and engineering professionals Dr. Randy Moore and Prof. Elena Di Martino along with MedTech entrepreneur Mr. Steven Arless, ViTAA Medical Solutions aims to tailor interventions and improve outcomes both pre- and post-EVAR (endovascular aneurysm repair) by identifying areas of aortic weakness which lead to rapid growth and negative AAA-related clinical events.

Using cardiac-gated CT imaging data, ViTAA’s revolutionary mapping solutions are based on over a decade of research and innovation conducted by Drs. Moore and Di Martino. ViTAA Medical Solutions will use machine learning and AI to assist surgeons and interventionists in their work, thereby allowing them to more precisely select and treat AAA patients.

ViTAA commenced operations in Montreal (Corporate Head Office) and Calgary in March 2020.

For more information on ViTAA Medical Solutions and its technology please contact ViTAA CEO Mitchel Benovoy at mitchelbenovoy vitaamedical.com.

*ViTAA RAW™ Maps is not yet available for clinical use. We are currently working with the FDA to obtain market authorization for sale in the US. A version of the tool that is designated for Research Use Only (RUO) is described here.